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Introduction
S. Nance and C. Lomas-Francis
The International Society of Blood Transfusion (ISBT) 
Working Party on Rare Donors was established in 1985 and 
is composed of experts in rare donor activities from many 
countries; its main focus is to ensure the availability of rare red 
blood cell (RBC) units for transfusion. Alloimmunization to 
RBC antigens may occur following transfusion or pregnancy. 
Provision of blood may become challenging when a patient 
has made an alloantibody to a high-prevalence antigen or 
made multiple antibodies to many more common antigens. To 
have blood readily available for such situations requires access 
to an inventory of extensively phenotyped blood as well as to 
a database of rare donors who can be recruited for donation. 
One way to accomplish this is to routinely screen donors to 
search for rare blood types. A library of these rare donors is 
maintained that contains information such as their antigenic 
profile, demographic information for recruitment, and the RBC 
units that they have donated (liquid and frozen). Managers 
who are members of the World Health Organization (WHO) 
International Rare Donor Panel (IRDP) can search the WHO 
IRDP database and request rare blood from the members in 
other countries who have the blood they need. Units are then 
shipped according to the specifications required by both the 
shipping and receiving countries. 
This issue of Immunohematology contains articles 
from many of the members of the ISBT Working Party on 
Rare Donors, detailing aspects of their country’s rare donor 
program(s) and their approach to making units from rare 
donors available for transfusion. The submitted articles appear 
alphabetically according to country name in issues Volume 32, 
Number 1, 2016, and Volume 32, Number 2, 2016, as Part I 
and Part II, respectively. 
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• Switzerland, Germany, and Austria
• United Kingdom
• United States
The authors were asked to provide information on several 
topics. First, they were asked to give details on the type of 
rare donor program that exists in their country (national, 
regional, or local) and to outline the history of their rare donor 
program(s) (year started, and collaboration if regional or local 
programs). Second, they were asked to provide data on the 
number of active rare donors, the number of new rare donors 
added from 2012 to 2014, the number of rare units shipped 
(both domestically and internationally), and the number 
of requests for rare blood not filled. The authors were asked 
to review patient cases where incompatible blood had to be 
transfused because antigen-negative blood was not available 
and to provide details on the outcome, prophylaxis given, 
number of known cases, and other relevant details of these 
cases that can be shared. The authors were also asked to share 
information about the incentives used in their country for 
rare donor recruitment. The Rhnull phenotype is recognized as 
the rarest of the rare donors in the world; the members were 
asked to quantify the number of such donors and provide the 
molecular background, if known. 
In the event that the readers of Immunohematology are 
caring for patients with rare blood requirements, we hope 
that this collection of articles will provide an insight into the 
challenges of providing rare blood and allow our readers to 
be better informed and knowledgeable about international 
activities in the area of rare donor programs. The articles 
in this issue also serve to highlight the similarities and the 
differences between the programs and how they are managed 
in other countries.
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Attention:  
State Blood Bank Meeting Organizers
If you are planning a state meeting and would like copies 
of Immunohematology for distribution, please send request, 
4 months in advance, to immuno@redcross.org.
Notice to Readers
All articles published, including communications and  
book reviews, reflect the opinions of the authors and do 
not necessarily reflect the official policy of the American 
Red Cross.
It is incredible and reassuring to observe the international 
support, cooperation, and collaborative efforts that occur 
across geographical and political boundaries when a patient is 
in need, especially when the need is for very rare blood.
We thank the authors of the articles for sharing their data 
and experiences and the entire ISBT Working Party for their 
commitment to making rare blood available whenever and 
wherever it is needed.
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